Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Capecitabine
Drug ID BADD_D00349
Description Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Indications and Usage For the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen. May also be used in combination with docetaxel for the treatment of metastatic breast cancer in patients who have failed to respond to, or recurred or relasped during or following anthracycline-containing chemotherapy. Capecitabine is used alone as an adjuvant therapy following the complete resection of primary tumor in patients with stage III colon cancer when monotherapy with fluroprymidine is preferred. The use or capecitabine in combination regimens for advanced gastric cancer is currently being investigated.
Marketing Status approved; investigational
ATC Code L01BC06
DrugBank ID DB01101
KEGG ID D01223
MeSH ID D000069287
PubChem ID 60953
TTD Drug ID D00HCQ
NDC Product Code 55111-893; 82920-001; 72205-007; 72485-205; 62331-043; 16714-467; 51407-640; 55111-496; 55111-497; 61269-475; 65162-844; 15308-0714; 54893-0002; 59651-205; 64980-277; 70756-815; 68001-487; 69097-949; 72205-006; 63482-099; 72969-094; 16729-072; 59923-721; 61269-470; 0054-0271; 69539-019; 0093-7473; 64980-276; 0054-0272; 69097-948; 72606-554; 53104-7618; 55512-0015; 0004-1100; 51407-639; 67877-459; 68001-488; 69539-020; 35369-0010; 16729-073; 51407-096; 62756-238; 62756-239; 65162-843; 67877-458; 59651-204; 72485-204; 72606-555; 49452-1713; 68554-0033; 0004-1101; 0093-7474; 51407-095; 60687-149; 0378-2511; 70756-816; 53183-4009; 54245-7014; 65129-1241; 81955-0001; 16714-468; 59923-722
UNII 6804DJ8Z9U
Synonyms Capecitabine | N(4)-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine | Xeloda
Chemical Information
Molecular Formula C15H22FN3O6
CAS Registry Number 154361-50-9
SMILES CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Colon cancer metastatic16.13.01.012; 07.21.01.0100.001086%Not Available
Necrotising oesophagitis07.04.05.0060.000672%Not Available
Hepatic mass09.01.08.0150.000168%Not Available
Subacute cutaneous lupus erythematosus23.03.02.020; 10.04.03.012; 15.06.02.0120.000504%Not Available
Paraneoplastic syndrome16.32.01.0090.000112%Not Available
Diabetic foot05.07.06.001; 24.04.03.015; 23.07.03.008; 17.09.04.006; 14.07.06.0010.000280%Not Available
Female genital tract fistula23.07.04.015; 21.10.05.009; 20.08.01.007; 07.11.05.004; 12.02.14.0100.000280%Not Available
Malignant peritoneal neoplasm07.21.03.005; 16.13.04.0050.000224%Not Available
Gallbladder enlargement09.03.02.0050.000168%Not Available
Metastatic squamous cell carcinoma16.16.01.0100.000112%Not Available
Lip exfoliation07.05.05.0200.000246%Not Available
Mucosal exfoliation08.01.06.0210.000112%Not Available
Stress cardiomyopathy24.04.04.026; 02.04.01.0120.001869%Not Available
Abdominal wall haematoma24.07.02.039; 07.16.05.0050.000112%Not Available
Apparent death08.01.03.0620.000112%Not Available
Oncologic complication16.32.03.0250.000224%Not Available
Interstitial granulomatous dermatitis23.03.15.007; 10.04.02.0160.000168%Not Available
Fingerprint loss23.03.03.0660.001153%Not Available
Penile erythema21.12.01.0170.000246%Not Available
Exposed bone in jaw15.02.04.0340.000504%Not Available
Prerenal failure24.06.02.025; 20.01.03.0220.000224%Not Available
Invasive ductal breast carcinoma21.05.01.021; 16.10.01.0130.000168%Not Available
Mucosal toxicity12.03.01.056; 08.01.06.0240.000504%Not Available
Toxic leukoencephalopathy17.13.02.012; 12.03.01.0590.000168%Not Available
Gastrointestinal wall thickening07.01.06.0320.000302%Not Available
Unmasking of previously unidentified disease08.01.03.0800.000168%Not Available
Steatohepatitis14.08.04.020; 09.01.07.0240.000168%Not Available
Non-cirrhotic portal hypertension24.08.06.003; 09.01.06.0190.000112%Not Available
Oral pigmentation07.05.05.0240.000414%Not Available
Tongue discomfort07.14.02.0190.000246%Not Available
The 29th Page    First    Pre   29 30 31    Next   Last    Total 31 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene